Overview

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Status:
Recruiting
Trial end date:
2023-10-08
Target enrollment:
Participant gender:
Summary
The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Canagliflozin
Fulvestrant